Listing of Claims

1-20. (Canceled)

21. (Previously presented) A method of ablating or killing normal, benign hyperplastic, and cancerous prostate epithelial cells comprising: providing a biological agent which binds to an outer membrane domain of prostate specific membrane antigen and contacting said cells with the biological agent under conditions effective to permit both binding of the biological agent to the outer membrane domain of the prostate specific membrane antigen and ablating or killing of said cells.

22. (Previously presented) A method according to claim 21, wherein the biological agent is an antibody or ligand.

23. (Previously presented) A method according to claim 21, wherein said contacting is carried out in a living mammal and comprises: administering the biological agent to the mammal under conditions effective to permit both binding of the biological agent to the outer membrane domain of the prostate specific membrane antigen and killing of said cells.

24. (Previously presented) A method according to claim 23, wherein said administering is carried out orally, parenterally, subcutaneously, intravenously or intramuscularly.

25. (Previously presented) A method according to claim 22, wherein an antibody is used in carrying out said method, the antibody being selected from the group consisting of a monoclonal antibody and a polyclonal antibody.

26. (Previously presented) A method according to claim 22, wherein the ligand is used in carrying out said method.

27. (Previously presented) A method according to claim 21, wherein the biological agent is bound to a substance effective to kill or ablate said cells upon binding of the biological agent to the outer membrane domain of the prostate specific membrane antigen of said cells.

28. (Previously presented) A method according to claim 27, wherein the substance effective to kill said cells is a cytotoxic agent.

29. (Previously presented) A method according to claim 28, wherein the cytotoxic agent is selected from the group consisting of a drug, a toxin, a radioactive substance, a chemotherapeutic, an enzyme and molecules of fungal, viral and bacterial origin.

30. (Previously presented) A method according to claim 21, wherein the biological agent is in a composition further comprising a physiologically acceptable carrier, diluent, or stabilizer.

31. (Previously presented) A method according to claim 21, wherein the biological agent is in a composition further comprising a pharmaceutically acceptable carrier, diluent, or stabilizer.

32 to 58. (Canceled)